These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 24203912)

  • 1. Anti-tuberculosis drug-induced liver injury in Shanghai: validation of Hy's Law.
    Shen X; Yuan Z; Mei J; Zhang Z; Guo J; Wu Z; Wu J; Zhang H; Pan J; Huang W; Gong H; Yuan D; Xiao P; Wang Y; Shuai Y; Lin S; Pan Q; Zhou T; Watkins PB; Wu F
    Drug Saf; 2014 Jan; 37(1):43-51. PubMed ID: 24203912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence of liver injury among cancer patients receiving chemotherapy in an integrated health system.
    Ulcickas Yood M; Bortolini M; Casso D; Beck JG; Oliveria SA; Wells KE; Woodcroft KJ; Wang LI
    Pharmacoepidemiol Drug Saf; 2015 Apr; 24(4):427-34. PubMed ID: 25683797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of multivariate outlier detection analyses used to identify potential drug-induced liver injury in clinical trial populations.
    Lin X; Parks D; Painter J; Hunt CM; Stirnadel-Farrant HA; Cheng J; Menius A; Lee K
    Drug Saf; 2012 Oct; 35(10):865-75. PubMed ID: 22928730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of Hy's law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury.
    Robles-Diaz M; Lucena MI; Kaplowitz N; Stephens C; Medina-Cáliz I; González-Jimenez A; Ulzurrun E; Gonzalez AF; Fernandez MC; Romero-Gómez M; Jimenez-Perez M; Bruguera M; Prieto M; Bessone F; Hernandez N; Arrese M; Andrade RJ; ; ;
    Gastroenterology; 2014 Jul; 147(1):109-118.e5. PubMed ID: 24704526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of drug-induced serious hepatotoxicity (eDISH): application of this data organization approach to phase III clinical trials of rivaroxaban after total hip or knee replacement surgery.
    Watkins PB; Desai M; Berkowitz SD; Peters G; Horsmans Y; Larrey D; Maddrey W
    Drug Saf; 2011 Mar; 34(3):243-52. PubMed ID: 21332248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of Acute Liver Failure in Patients With Drug-Induced Liver Injury: Evaluation of Hy's Law and a New Prognostic Model.
    Lo Re V; Haynes K; Forde KA; Goldberg DS; Lewis JD; Carbonari DM; Leidl KB; Reddy KR; Nezamzadeh MS; Roy J; Sha D; Marks AR; De Boer J; Schneider JL; Strom BL; Corley DA
    Clin Gastroenterol Hepatol; 2015 Dec; 13(13):2360-8. PubMed ID: 26122767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In silico modeling to optimize interpretation of liver safety biomarkers in clinical trials.
    Church RJ; Watkins PB
    Exp Biol Med (Maywood); 2018 Feb; 243(3):300-307. PubMed ID: 29096561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A proposed modification to Hy's law and Edish criteria in oncology clinical trials using aggregated historical data.
    Parks D; Lin X; Painter JL; Cheng J; Hunt CM; Spraggs CF; Nelson JJ; Curtis L; Menius JA; Lee KR
    Pharmacoepidemiol Drug Saf; 2013 Jun; 22(6):571-8. PubMed ID: 23300062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liver Safety of Fasiglifam (TAK-875) in Patients with Type 2 Diabetes: Review of the Global Clinical Trial Experience.
    Marcinak JF; Munsaka MS; Watkins PB; Ohira T; Smith N
    Drug Saf; 2018 Jun; 41(6):625-640. PubMed ID: 29492878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A retrospective study to evaluate Hy's Law, DrILTox ALF score, Robles-Diaz model, and a new logistic regression model for predicting acute liver failure in Chinese patients with drug-induced liver injury.
    Xiong X; Xu Q; Wang B
    Expert Opin Drug Saf; 2024 Feb; 23(2):207-211. PubMed ID: 36958375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Pattern of Tolvaptan-Associated Liver Injury in Trial Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD): An Analysis of Pivotal Clinical Trials.
    Alpers DH; Lewis JH; Hunt CM; Freston JW; Torres VE; Li H; Wang W; Hoke ME; Roth SE; Westcott-Baker L; Estilo A
    Am J Kidney Dis; 2023 Mar; 81(3):281-293.e1. PubMed ID: 36191725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug-Induced Liver Injury from Anti-Tuberculosis Treatment: A Retrospective Cohort Study.
    Zhao H; Wang Y; Zhang T; Wang Q; Xie W
    Med Sci Monit; 2020 Mar; 26():e920350. PubMed ID: 32145061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonsteroidal anti-inflammatory drug-induced hepatoxicity.
    Unzueta A; Vargas HE
    Clin Liver Dis; 2013 Nov; 17(4):643-56, ix. PubMed ID: 24099022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence of antituberculosis-drug-induced hepatotoxicity and associated risk factors among tuberculosis patients in Dawro Zone, South Ethiopia: A cohort study.
    Wondwossen Abera ; Waqtola Cheneke ; Gemeda Abebe
    Int J Mycobacteriol; 2016 Mar; 5(1):14-20. PubMed ID: 26927985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A simple method to identify undiagnosed drug-induced liver injury (DILI) and its application in oncology pharmacy practice.
    Wen H; Ge M; Yao D; Liu L
    J Oncol Pharm Pract; 2020 Jul; 26(5):1060-1069. PubMed ID: 31684820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence, clinical features and impact on anti-tuberculosis treatment of anti-tuberculosis drug induced liver injury (ATLI) in China.
    Shang P; Xia Y; Liu F; Wang X; Yuan Y; Hu D; Tu D; Chen Y; Deng P; Cheng S; Zhou L; Ma Y; Zhu L; Gao W; Wang H; Chen D; Yang L; He P; Wu S; Tang S; Lv X; Shu Z; Zhang Y; Yang Z; Chen Y; Li N; Sun F; Li X; He Y; Garner P; Zhan S
    PLoS One; 2011; 6(7):e21836. PubMed ID: 21750735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determination of fasiglifam-induced liver toxicity: Insights from the data monitoring committee of the fasiglifam clinical trials program.
    Shavadia JS; Sharma A; Gu X; Neaton J; DeLeve L; Holmes D; Home P; Eckel RH; Watkins PB; Granger CB
    Clin Trials; 2019 Jun; 16(3):253-262. PubMed ID: 30880443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hy's law: predicting serious hepatotoxicity.
    Temple R
    Pharmacoepidemiol Drug Saf; 2006 Apr; 15(4):241-3. PubMed ID: 16552790
    [No Abstract]   [Full Text] [Related]  

  • 19. Co-infection with hepatitis B virus among tuberculosis patients is associated with poor outcomes during anti-tuberculosis treatment.
    Chen L; Bao D; Gu L; Gu Y; Zhou L; Gao Z; Huang Y
    BMC Infect Dis; 2018 Jul; 18(1):295. PubMed ID: 29970037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatotoxicity Due to Antituberculosis Therapy among Paediatric Patients Seen at the University of Ilorin Teaching Hospital, North Central Nigeria.
    Aishatu G; Rasheedah I; Wahab J; Sheni M; Damilola O; Adeniyi O
    Ethiop J Health Sci; 2017 Mar; 27(2):115-120. PubMed ID: 28579706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.